KALARIS THERAPEUTICS INC (KLRS:NASDAQ)
$3.51 0.03 (0.8621%)
Analysed KALARIS THERAPEUTICS INC (KLRS:NASDAQ) News Sources
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
28-01-2026
yahoo.com
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
17-03-2026
yahoo.com
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
12-05-2026
yahoo.com
Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls
14-05-2026
yahoo.com
Kalaris to Present at Clinical Trials at the Summit 2026
12-06-2026
yahoo.com
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
23-06-2026
yahoo.com
Kalaris Appoints Laurie Keating to Board of Directors
06-07-2026
yahoo.com
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
14-07-2026
yahoo.com
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
17-07-2026
yahoo.com
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
20-07-2026
yahoo.com
What is the current price of KALARIS THERAPEUTICS INC (KLRS:NASDAQ)?
The current price of KALARIS THERAPEUTICS INC (KLRS:NASDAQ) is $3.51.
KALARIS THERAPEUTICS INC (KLRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of KALARIS THERAPEUTICS INC (KLRS:NASDAQ) since the previous trading day is $0.03.
KALARIS THERAPEUTICS INC (KLRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of KALARIS THERAPEUTICS INC (KLRS:NASDAQ) since the previous trading day is 0.8621%.
What is the most recent average sentiment score for KALARIS THERAPEUTICS INC (KLRS:NASDAQ)?
The most recent average sentiment score for KALARIS THERAPEUTICS INC (KLRS:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for KALARIS THERAPEUTICS INC (KLRS:NASDAQ)?
The most recent sentiment for KALARIS THERAPEUTICS INC (KLRS:NASDAQ) is .
SEC-8K** Filing Available For KALARIS THERAPEUTICS INC (KLRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.